Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transfer factor in ACLD and ACLF
NCT02837939Phase 3Withdrawn
- Start
- Jul 2016
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Transferon in chronic liver disease (CLD) and acute-on-chronic liver failure (ACLF). Primary endpoint: Incidence of specified infections at 2 years. Planned start Jul 2016; status: withdrawn.
02
Drugs
Transferon
03
Conditions
chronic liver disease (CLD)acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT02837939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837939.